Your browser doesn't support javascript.
loading
Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma.
Pinnix, Chelsea C; Milgrom, Sarah A; Cheah, Chan Yoon; Gunther, Jillian R; Ludmir, Ethan B; Wogan, Christine F; Nastoupil, Loretta J; Neelapu, Sattva S; Westin, Jason; Lee, Hun J; Iyer, Swaminathan P; Steiner, Raphael E; Fayad, Luis E; Fowler, Nathan H; Wang, Michael L; Samaniego, Felipe; Rodriguez, Maria A; Rich, Amy E; Medeiros, L Jeffrey; Dabaja, Bouthaina S.
Afiliación
  • Pinnix CC; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Milgrom SA; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Cheah CY; Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
  • Gunther JR; Department of Haematology, Pathwest Laboratory Medicine, Nedlands, WA, Australia.
  • Ludmir EB; Medical School, University of Western Australia, Crawley, WA, Australia.
  • Wogan CF; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Nastoupil LJ; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Neelapu SS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Westin J; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Lee HJ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Iyer SP; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Steiner RE; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Fayad LE; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Fowler NH; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Wang ML; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Samaniego F; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Rodriguez MA; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Rich AE; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Medeiros LJ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Dabaja BS; Orlando Regional Medical Center, Orlando, FL; and.
Blood Adv ; 3(9): 1356-1367, 2019 05 14.
Article en En | MEDLINE | ID: mdl-31036721
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Linfocitos Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Adv Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Linfocitos Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Adv Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos